Navigation

Chronic obstructive pulmonary disease - roflumilast

Roflumilast for the maintenance treatment of severe chronic obstructive pulmonary disease (COPD)

Status: History
Expected date of issue: January 2012
Referral date: June 2010
Process: STA
Topic area:
  • Respiratory
 

NICE project team

Executive Lead: Gillian Leng
Technical Lead: Helen Starkie
Communications manager: Katie Williamson
Project manager: Bijal Joshi
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 2 December 2010
1st appraisal committee meeting: 17 August 2011
2nd appraisal committee meeting 19 October 2011
Top


 

Consultees and commentators

Consultees

Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Merck Sharp & Dolme UK Ltd (roflumilast)

Patient/carer groups

  • Action on Smoking
  • Afiya Trust
  • Black Health Agency
  • British Lung Foundation
  • Chinese National Healthy Living Centre
  • Counsel and Care
  • Equalities National Council
  • Muslim Council of Britain
  • Muslim Health Network
  • QUIT
  • South Asian Health Foundation
  • Specialised Healthcare Alliance

Professional groups

  • Association of Respiratory Nurse Specialists
  • British Association for Services to the Elderly
  • British Geriatrics Society
  • British Thoracic Society
  • Primary Care Respiratory Society UK
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
  • Royal Pharmaceutical Society
  • Royal Society of Medicine – Intellectual Disabilities Forum
  • United Kingdom Clinical Pharmacy Association

Others

  • Department of Health
  • Rhondda Cynon Taff LHB
  • Trafford Healthcare NHS Trust
  • Welsh Assembly Government

General

  • Board of Community Health Councils in Wales
  • British National Formulary
  • Care Quality Commission
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency
  • National Association of Primary Care
  • NHS Alliance
  • NHS Commercial Medicines Unit
  • NHS Confederation
  • NHS Quality Improvement Scotland
  • Public Health Wales NHS Trust
  • Scottish Medicines Consortium

Comparator manufacturers

  • 3M Health Care (theophylline)
  • AstraZeneca (symbicort, formoteral)
  • Boehringer Ingelheim (tiotropium)
  • Chiesi (fostair, formoterol)
  • Goldshield (aminophylline)
  • GlaxoSmithKline (seretide, salmeterol)
  • Hameln (aminophylline)
  • Meda Pharmaceuticals (theophylline)
  • Merck Serono (theophylline)
  • Napp Pharmaceuticals (aminophylline, theophylline)
  • Novartis (formoterol, theophylline)
  • Orion Pharma (formoterol)
  • Sanofi-Aventis (theophylline)
  • Teva UK (aminophylline)
  • UCB (aminophylline)

Relevant research groups

  • Cochrane Airways Group
  • MRC Clinical Trials Unit
  • National Institute for Health Research
  • Policy Research Institute on Aging and Ethnicity
  • Research Institute for the Care of Older People

Evidence Review Group

  • School of Health & Related Research Sheffield (ScHARR)
  • National Institute for Health Research
  • Health Technology Assessment Programme

Associated Guideline Groups

  • None

Associated Public Health Groups

  • None

Top


 

Project history

Date Update
3 February 2011

Due to resource constraints and efficiency scheduling requirements for the current work programme, NICE has had to decide to re-schedule the first Appraisal Committee meeting for a number of the technology appraisal topics.

In rescheduling these topics we have been careful to maintain our ability to issue timely recommendations.

The appraisal of Roflumilast for the maintenance treatment of severe chronic obstructive pulmonary disease (COPD) is one of the topics that has been identified.

The first appraisal committee discussion will now take place on 17 August 2011.  The second committee meeting (if required) will also take place on 19 October 2011.

All the other arrangements for the topic will remain as earlier communicated.

Please contact the project manager Bijal Joshi if you have questions about the new timelines or the associate director Janet Robertson for policy queries.

Top


 

Key documents

This page was last updated: 27 April 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.